Agenus Q2 net loss narrows to $49M; botensilimab shows 24% ORR in MSS CRC

AGENUS INC

2022-Q2 EPS reported -$0.35 revenue$46,867,000

Net loss of $49.2M ($0.17/share) vs $84.0M ($0.37) in Q2 2021; revenue $20.9M (up from $10.7M).
Cash & investments $238M at June 30, 2022, down from $307M at Dec 31, 2021.
Botensilimab/balstilimab combo achieved 24% ORR and 73% DCR in 41 heavily pretreated MSS CRC patients.
Phase 2 randomized trials in MSS CRC, melanoma, and pancreatic cancer to start later this year.
First patient dosed in Phase 1 study of AGEN1571 (anti-ILT2) in advanced solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.